A comparative study of growth hormone (GH) and GH‐releasing hormone(1–29)‐NH2 for stimulation of growth in children with GH deficiency

@article{Chen1993ACS,
  title={A comparative study of growth hormone (GH) and GH‐releasing hormone(1–29)‐NH2 for stimulation of growth in children with GH deficiency},
  author={R‐G Chen and Y‐N Shen and J. Yei and C. Wang and D‐H Xie and X‐H Wang and J‐D Zhou and C‐Y Chen and Y‐L Wu and R. Gunnarsson and K. Danielson and Y. Chardet},
  journal={Acta P{\ae}diatrica},
  year={1993},
  volume={82}
}
In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone‐releasing hormone(1–29)‐NH, (GHRH(1–29)‐NH,), 30 or 60 μg/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months. There were no significant differences in growth between the two groups given GHRH(1–29)‐NH, but growth in the GH group was significantly better than in the other two groups (p< 0.01). Mean height velocities at 6… Expand
Effects of long‐term growth hormone releasing hormone 1 ‐29 in significantly short children
TLDR
It is demonstrated that some patients with SISS grow well during the first 2 years of treatment with GH‐RH. Expand
Long-Term Treatment with GHRH [1-44] Amide in Prepubertal Children with Classical Growth Hormone Deficiency
TLDR
It is concluded that twice-daily GHRH treatment in a small group of prepubertal GH deficient children resulted in sustained improvement in height and growth velocity, and achieved height SDS approaching closely those of their parents. Expand
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
  • A. Prakash, K. Goa
  • Medicine
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • 1999
TLDR
Sermorelin is a well tolerated analogue of GHRH which is suitable for use as a provocative test of growth hormone deficiency when given as a single intravenous 1 microg/kg bodyweight dose in conjunction with conventional tests. Expand
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
TLDR
Treatment with tesamorelin was generally well tolerated and resulted in sustained decreases in VAT and triglycerides over 52 weeks without aggravating glucose, though effects on VAT are sustained during treatment for 52 weeks, these effects do not last beyond the duration of treatment. Expand
Tesamorelin, a human growth hormone releasing factor analogue
TLDR
Tesamorelin might be a beneficial treatment strategy for HIV-related lipodystrophy with a good safety profile and a positive effect on reducing visceral fat, and other potential indications appear less promising from the current data. Expand
PEGylation of growth hormone-releasing hormone (GRF) analogues.
TLDR
It was found that GRF-PEG conjugates are able to bind and activate the human GRF receptor, although with different potency, and their bioactivity was tested in vitro and in vivo. Expand
Treatment of radiation‐induced growth hormone deficiency with growth hormone‐releasing hormone
In children with hypothalamic causes for GH deficiency there are theoretical reasons why a GHRH analogue might be better than conventional GH therapy in promoting growth.
Pathophysiologie und Klinik des gestörten Längenwachstums
Richtungsweisende Bedeutung hat zunachst die Anamnese; sie wird herausfinden, ob ein vermeintliches oder tatsachliches Mindermas schon von Geburt an oder erst spater auffiel, ob Erkrankungen in derExpand
Traitement des déficits en hormone de croissance par le facteur hypothalamique de libération de l'hormone de croissance. État actuel et perspectives
TLDR
L'approche therapeutique par des facteurs de liberation de l'hormone de croissance differents du GRF parait prometteuse, mais pourrait etre complementaire de celle del GRF plus que concurrentielle. Expand

References

SHOWING 1-10 OF 10 REFERENCES
Sustained improvement in growth velocity and recovery from suboptimal growth hormone (GH) secretion after treatment with human pituitary GH-releasing hormone-(1-44)-NH2.
TLDR
The increased growth velocity that was sustained for long intervals even after discontinuation of GHRH in ISGHS patients may indicate restoration of normal regulation of the hypothalamic-pituitary GH secretion axis. Expand
Results of 1-year growth hormone (GH)-releasing hormone-(1-44) treatment on growth, somatomedin-C, and 24-hour GH secretion in six children with partial GH deficiency.
TLDR
The results indicate that GHRH administered by sc injection for a 1-yr period stimulated growth and GH secretion, however, a decrease in activity was noted during the last 3 months of treatment. Expand
TREATMENT OF GROWTH-HORMONE DEFICIENCY WITH GROWTH-HORMONE-RELEASING HORMONE
TLDR
GHRH (1-29) NH2 therapy is an alternative to conventional hGH in the treatment of some GH-deficient children and there was no consistent evidence of a priming or desensitisation effect of therapy on the GH responses to GHRH. Expand
SUBCUTANEOUS GROWTH HORMONE‐RELEASING HORMONE AUGMENTS PULSATILE NOCTURNAL GH RELEASE IN GH‐INSUFFICIENT CHILDREN, BUT MAY ALSO RAISE BASAL GH SECRETION
TLDR
The results suggest that a sustained release preparation of GHRH could be a potential treatment for GH‐insufficient children, and that a dose of 5 μg/kg/h would promote pulsatile GH release, but that at higher dosage it may also raise basal GH secretion. Expand
NOCTURNAL PULSATILE GROWTH HORMONE RELEASING HORMONE TREATMENT IN GROWTH HORMONE DEFICIENCY
TLDR
Pulsatile administration of GHRH1–40 is effective in inducing GH secretion and promoting growth acceleration in some children with idiopathic GH deficiency and the optimal doses and mode of administration have yet to be established. Expand
Modification of 24‐Hour Growth Hormone Secretion after Continuous Subcutaneous Infusion of Growth Hormone‐Releasing Hormone (GHRH (1–29)NH2) in Short Children with Low 24‐Hour Growth Hormone Secretion
TLDR
Modification of 24‐hour growth hormone secretion after continuous subcutaneous infusion of growth hormone‐releasing hormone (GHRH (1–29)NH2) in short children with low 24-hour growth hormones secretion is studied. Expand
Use of Continuous Subcutaneous Growth Hormone‐Releasing Hormone (GHRH (1–29)NH2) Infusions to Augment Growth Hormone Secretion and to Promote Growth
TLDR
Use of continuous subcutaneous growth hormone‐releasing hormone (GHRH) infusions to augment growth hormone secretion and to promote growth. Expand
Acceleration of growth in two children treated with human growth hormone-releasing factor.
TLDR
Growth hormone--releasing factor can restore growth hormone secretion and its biologic effects, including an increase in nitrogen retention, an increaseIn serum somatomedin C, and acceleration of linear growth in children with growth hormone deficiency. Expand
CONTINUOUS SUBCUTANEOUS GROWTH HORMONE RELEASING FACTOR ANALOGUE AUGMENTS GROWTH HORMONE SECRETION IN NORMAL MALE SUBJECTS WITH NO DESENSITIZATION OF THE SOMATOTROPH
TLDR
The effects of 8 day continuous subcutaneous infusions of growth hormone releasing hormone analogue (NLE27GRF(1–29)NH2 (GHRH.A)) on growth hormone (GH) secretion were studied in 14 normal adult male volunteers and the possibility of treatment of short children with depot preparations of GHR H.A appears promising. Expand
Nine Months' Subcutaneous Therapy with Synthetic Growth Hormone Releasing Factor in Children with Short Stature
TLDR
GRF dose and frequency of administration were probably suboptimal in this group of patients; higher dose frequencies might be necessary to achieve growth rates comparable with those observed during hGH substitution therapy. Expand